Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
about
Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateEstablishment of a novel human lymphoblastic cell strain with the long arm of chromosome 11 aberration without MLL rearrangement.The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.Clinical Significance of "Double-hit" and "Double-protein" expression in Primary Gastric B-cell Lymphomas.MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphomaSPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathwayHighly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?Early relapse in a case of primary bone marrow diffuse large B-cell lymphoma treated with rituximab-CHOP.Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomasMYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.Aggressive lymphoma presenting as dysphagia: A rare cause of dysphagia.Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.Estrogen receptor beta expression and prognosis of diffuse large B cell lymphoma.A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.Nuances in the Management of Aggressive Lymphomas.Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOPGeneration and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapiesSpanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
P2860
Q28078869-1FA7BE59-3733-426C-B23B-770EED19C279Q33678485-EEFCD891-883E-40B4-8FB3-80F53B1E16C0Q36559885-E529BB74-A0DF-47CF-B338-C97DD893674BQ37067986-CB26BD0A-749A-4C9C-B81B-50702661C58AQ37142412-36D170F3-4798-4B68-B7A1-D55BDDB4A22AQ37252312-C379829F-4A4C-48EF-A4B8-3C8CAAAA2F94Q37687767-23C12CB5-8629-44B4-AEE3-F45B5CFA704EQ38656983-7B370D11-52A0-4B37-8D3D-A39255650E53Q40063229-E96F8938-3F20-4C58-A984-F8A29CC3F7CFQ40507970-A7FCEA3F-E085-412E-9F60-478DF2F9A8ACQ40974570-51C10689-24D8-41A2-B94A-656E075C2911Q41316559-BDF77B93-0A19-4346-9826-BC1A0239F27DQ42289936-85BA3F2E-86CA-411B-96D3-D8B9A0D1B0FAQ43525091-E562A4AC-C2BE-4394-B99A-10213A3484B8Q47589672-A6D80FFD-863D-4B00-A754-F47A3C8F0AEDQ47618290-B7F77939-FE45-4ADF-8EA3-56FEB159F341Q47634902-8376E622-0438-42FD-825C-C7559E28B2F3Q47651447-89496FE3-7F25-49B7-B2F8-8ADC3B6A1A91Q48018366-1BF9C4F8-E8BF-4B9A-9EC8-ED3A7C2DD25FQ52659471-B42ECD86-93FA-4222-9000-4C817160023EQ52760136-22E3B019-D0D5-4FD5-90C0-4DCD10DF97EEQ54863084-F530E38B-CE4A-4B5E-9BCE-8EB23DE5FE0EQ55282730-A4EAC19A-8E9F-4801-BC22-BA2E84AE66D0Q57031907-CFBFA377-FCE7-42EE-8D99-0008ECDD7D29Q57493686-1E223835-E768-4787-B2C8-4624F4D75130Q58767936-832C15D8-C342-4DEA-B7D0-EA8E449414EF
P2860
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
@en
type
label
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
@en
prefLabel
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
@en
P1433
P1476
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
@en
P2093
Alexandra Traverse-Glehen
Bertrand Coiffier
P304
P356
10.1016/S1470-2045(15)00005-4
P577
2015-11-01T00:00:00Z